The Boston Globe |
Sanofi ends marketing deal with developer of inhaled insulin
The Boston Globe MannKind, based in Valencia, Calif., said in a news release Tuesday that the companies would try to effect a smooth transition of the marketing rights from Sanofi to MannKind, to be completed in no later than six months. It said it was reviewing its ... Sanofi to stop marketing Afrezza, citing low Rx MannKind plans to seek new marketing partner for insulin drug |
January 05, 2016 at 10:32PM | marketing - Google News
Sanofi ends marketing deal with developer of inhaled insulin - The Boston Globe
marketing - Google News
Nenhum comentário:
Postar um comentário